Stock data

南光 (1752)

南光 is a TWSE-listed company in Biotech & Medical Care. Revenue for September 2026 was NT$162.08M, down 14.4% from a year earlier. EPS over the last four quarters totals NT$2.03.

Charts, drawing tools, and the P/E calculator are in the app, free to use.

Open 南光 in Insightr